Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Notable Analyst Rating Changes 10/27: (AAN) (GRMN) (FLIR) Upgraded; (DO) (DNR) (COMM) Downgraded
-
Chardan Capital Markets Downgrades EZchip Semiconductor (EZCH) to Neutral; Q4:14 Consensus at Risk
-
Unusual 11 Mid-Day Movers 10/22: (RGLS) (ZAZA) (VPCO) Higher; (WG) (NSPH) (BDBD) Lower
-
Pre-Open Stock Movers 10/22: (RGLS) (IRBT) (SIX) (BRCM) Higher; (NSPH) (DDD) (HIMX) (LL) Lower (more...)
-
Nanosphere (NSPH) Prices 40M Common Offering at 50c/Share
-
Himax (HIMX) News Suggests Google (GOOG) Looking at Different Direction for Google Glass, Chardan Capital Says; Sell the Stock
-
After-Hours Stock Movers 10/21: (UIS) (SIX) (BRCM) (YHOO) Higher; (NSPH) (HIMX) (CREE) (TSLA) Lower (more...)
-
UPDATE: Nanosphere (NSPH) Commences Common Stock Offering, Prelim. Q3 Revs Top Expectations
-
Nanosphere Announces Commencement of Public Offering of Common Stock; Preliminary Third Quarter 2014 Top Line Results
-
Chardan Affirms Himax (HIMX) at 'Sell'; Slow Smartphone Sales, Capacity Constraints Could Impact Stock
-
Kerrisdale's Case Against Golbalstar (GSAT) Still has Serious Flaws - Chardan Capital
-
Streetinsider.com's Hot Lunchtime Reads 10/9: (NNVC) (PLUG) (CRM) (DYNT)
-
NanoViricides (NNVC) Restarts Ebola Program; Chardan Capital Maintains 'Buy' Rating
-
PlacementTracker Publishes Third Quarter 2014 PIPE Market League Tables
-
Chardan Global Keeps Rockwell Medical (RMTI) at 'Buy'; Baxter Agreement Eliminates Financing Risk
-
Chardan Capital Trims PT on IDT Corp. (IDT) to $17 Following Q4 Results, Outlook
-
Chardan Capital Affirms EZchip Semi (EZCH) at 'Buy' Following Lowered Q3 Outlook
-
Chardan Capital Positive on Hemispherx (HEB) Following Expanded Ebola Collaborations
-
Streetinsider.com's Hot Lunchtime Reads 10/2: (SCTY) (TSEM) (RCAP) (ADSK)
-
Chardan Capital Says to Buy Towerjazz (TSEM), Sell Himax (HIMX) as Q414 Begins
-
Chardan Capital Defends Globalstar (GSAT); Partnerships Only Question Mark Following FCC Ruling
-
Streetinsider.com's Hot Lunchtime Reads 9/25: (MU) (ACOR) (ADNC) (AAPL)
-
Chardan Cuts PT on Audience (ADNC) to $8; iPhone 6 Success May Equal Lower Sales for Key Customer
-
Chardan Capital Remains Positive on Endocyte (ECYT) into 2014 ESMO Congress
-
Chardan Capital Markets Starts Abtech Holdings (ABHD) at Buy
-
22nd Century Group (XXII) Closes 3.87M Common Private Placement
-
Medivation (MDVN) PT Lifted to $122 at Chardan Capital Markets
-
Streetinsider.com's Hot Lunchtime Reads 9/9: (HD) (MBLY) (CRM) (EL)
-
Chardan Lowers PT on MaxLinear (MXL) to $7.50 Following Updated Q3 Guidance
-
Chardan Positive on Strong Sales Price for iPass (IPAS); Affirms 'Buy' Rating
-
Ambarella (AMBA) PT Raised to $35 at Chardan Capital Markets; 'Neutral' Maintained
-
Chardan Sees China Mobile Subs Growth, Cut Subsidies Adding to Himax (HIMX) Weakness in H214
-
CHardan Remains Positive, Comments on Profire (PFIE) Following Q1 Results
-
Chardan Capital Markets Starts Medical Transcription Billing (MTBC) at Buy
-
Globalstar (GSAT) Buy Rating Reiterated at Chardan Capital (Earlier)
-
MTBC to Release Q2 2014 Financial Results on August 27, 2014
-
Streetinsider.com's Hot Lunchtime Reads 08/07: (TWX) (HIMX) (SRPT) (AAPL)
-
Himax (HIMX) Q2 Results, Q3 Guidance Were Solid, but Google Glass Remains 2015 Event - Chardan Capital
-
Notable Analyst Rating Changes 08/07: (AOL) (CAT) (CCL) Upgraded; (AET) (XXIA) (NUS) Downgraded
-
Chardan Affirms ARIAD (ARIA) at 'Buy'; Narrower Label Impacts Iclusig Usage
-
Chardan Capital Markets Starts MOKO Social Media (MOKO) at Buy
-
Margin Pressure Could Clip Himax's (HIMX) Q2 Profit and Hamper Outlook - Chardan Capital
-
Chardan Capital Markets Downgrades Audience, Inc. (ADNC) to Neutral
-
Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update
-
MTBC Announces Concurrent Closings of Initial Public Offering on NASDAQ and Three Strategic Asset Purchases
-
La Jolla Pharma (LJPC) Poised to Open Lower After 5.4M Offering Prices at $10.50/Share
-
La Jolla Pharmaceutical (LJPC) Prices 4.8M Common Offering at $10.50/Share
-
Chardan Cuts PT on Himax (HIMX) to $4.50; Weak Q3 Guidance Expected; Google Mum on Glass
-
MTBC Announces Pricing of Initial Public Offering
-
Nuvilex Provides Shareholder Update on Milestone Accomplishments

